Real-World Treatment Outcomes After Nivolumab Progression in BRAF-Negative Metastatic Melanoma: A Multicenter Cohort Study by the Turkish Oncology Group.

Eniseler EB, Erdogan AP, Şahbazlar M, Keskin Uzundere F, Şakalar T, Gür HB, Hacıbekiroğlu İ, Balcık OY, Beypınar İ, Savsar MG, Pempe G, Oksuz S, Başoğlu T, Demirkıran Ö, Demir B, Açıkgöz Yıldız B, Demiray AG, Akarca MS, Ünek İT, Kara M, Urun M, Gökay AC, Yeşil H, Ekinci F

Open source

DOI: 10.3390/jcm15135224
Published: 2026 Jul 3
Container: Journal of clinical medicine
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3390/jcm15135224,
  title = {Real-World Treatment Outcomes After Nivolumab Progression in BRAF-Negative Metastatic Melanoma: A Multicenter Cohort Study by the Turkish Oncology Group.},
  author = {Eniseler EB and Erdogan AP and Şahbazlar M and Keskin Uzundere F and Şakalar T and Gür HB and Hacıbekiroğlu İ and Balcık OY and Beypınar İ and Savsar MG and Pempe G and Oksuz S and Başoğlu T and Demirkıran Ö and Demir B and Açıkgöz Yıldız B and Demiray AG and Akarca MS and Ünek İT and Kara M and Urun M and Gökay AC and Yeşil H and Ekinci F},
  year = {2026},
  journal = {Journal of clinical medicine},
  doi = {10.3390/jcm15135224},
  url = {https://doi.org/10.3390/jcm15135224}
}

RIS

TY  - JOUR
TI  - Real-World Treatment Outcomes After Nivolumab Progression in BRAF-Negative Metastatic Melanoma: A Multicenter Cohort Study by the Turkish Oncology Group.
AU  - Eniseler EB
AU  - Erdogan AP
AU  - Şahbazlar M
AU  - Keskin Uzundere F
AU  - Şakalar T
AU  - Gür HB
AU  - Hacıbekiroğlu İ
AU  - Balcık OY
AU  - Beypınar İ
AU  - Savsar MG
AU  - Pempe G
AU  - Oksuz S
AU  - Başoğlu T
AU  - Demirkıran Ö
AU  - Demir B
AU  - Açıkgöz Yıldız B
AU  - Demiray AG
AU  - Akarca MS
AU  - Ünek İT
AU  - Kara M
AU  - Urun M
AU  - Gökay AC
AU  - Yeşil H
AU  - Ekinci F
PY  - 2026
JO  - Journal of clinical medicine
DO  - 10.3390/jcm15135224
UR  - https://doi.org/10.3390/jcm15135224
ER  -

APA

EB, E., AP, E., M, Ş., F, K. U., T, Ş., HB, G., İ, H., OY, B., İ, B., MG, S., G, P., S, O., T, B., Ö, D., B, D., B, A. Y., AG, D., MS, A., İT, Ü., M, K., M, U., AC, G., H, Y., & F, E. (2026). Real-World Treatment Outcomes After Nivolumab Progression in BRAF-Negative Metastatic Melanoma: A Multicenter Cohort Study by the Turkish Oncology Group.. Journal of clinical medicine. https://doi.org/10.3390/jcm15135224

Source records

pubmed · retrieved 2026-09-27T12:19:47.374Z
europe-pmc · retrieved 2026-09-27T12:19:47.393Z